- Global Pharma News & Resources

Anti-β-Alzheimer Therapies Market 2020 Size, Overview, Analysis, Key Methodologies, Top Players Success Milestones and Forecasts to 2026

Alzheimer’s disease (AD) is a type of neurological disorder that mainly affects thinking, memory, language, and behavior. This disease mainly occurs in people who are above 65 age and older and it has mild symptoms but results in severe brain damage in which individuals lose the ability to speak properly and respond to the environment. According to the Alzheimer Association, 2017, more than 5.5 million Americans are suffering from Alzheimer’s dementia. An estimated 5.3 million are age 65 and older and approximately 200,000 individuals are under age 65 and have the onset of Alzheimer’s. Alzheimer’s cognitive and behavioral symptoms can be treated by using non-drug treatment and symptomatic based medications. However, specific treatment for Alzheimer’s disease is not available in the market, which creates an opportunity for the development of Anti- β- Alzheimer therapies.

For more Information, Request PDF Brochure @

Global Anti-β-Alzheimer Therapies Market Taxonomy:

By Drug:

  • Aducanumab
  • Bapineuzumab
  • Solanezumab

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @

A breakthrough therapy is expected to offer immense growth for the Anti-β-Alzheimer therapies market

In July 2015, Biogen Pharmaceuticals announced results from a prespecified interim analysis of PRIME, which was the Phase 1b placebo-controlled study of aducanumab in patients with prodromal or mild Alzheimer’s disease (AD). Phase I clinical trials were conducted on 166, patients, which showed significant progress by lowering of Amyloid beta levels in the brain and slowdown in cognitive function as compared to the control group who received a placebo. Phase III efficacy trial showed significant cognitive results in FDA based specific memory tests. On the other hand, in 2016, Eli Lilly and Company announced the development of Alzheimer’s drug solanezumab, which was in phase III clinical trial due to its slow progression of Alzheimer’s disease and high cost.

In 2012, Pfizer Inc. and Johnson & Johnson announced to discontinue the development of Alzheimer’s drug which was in intravenous (IV) form – bapineuzumab as drug failed to help the patient with the memory-robbing condition in a second high profile clinical trial. Such failures, limit the growth of a market.

To understand Research Methodology, please click

Rising prevalence and incidence of Alzheimer disease is projected to favor the growth of Anti-β-Alzheimer therapies market

A growing aging population along with its associated complications, such as dementia is the major driving factor for the growth of the Anti-β-Alzheimer therapies market. For instance, according to Centers for Disease Control and Prevention (CDC), 2013, five million Americans were suffering from AD and the number is expected to rise up to 14 million by 2050. Moreover, according to the World Health Organization (WHO), 2017, approximately 47 million people have dementia and nearly 10 million new cases are reported annually.

According to the Australian Bureau of Statistics (ABS) in 2013, dementia was the second leading cause of death in Australia. According to the Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach around 400,000 by 2020, and around 900,000 by 2050. The National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to priorities and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment and care for dementia patients. Rising prevalence and incidence of Alzheimer disease and its complication worldwide and growing demand for therapy is projected to favor the growth of Anti-β-Alzheimer therapies market in the near future.

Biogen Pharmaceuticals is a key player dominating the global Anti-β-Alzheimer therapies market.

Table of Content

Global Anti-β-Alzheimer Therapies Market Research Report
Section 1: Global Anti-β-Alzheimer Therapies Industry Overview
Section 2: Global Economic Impact on Anti-β-Alzheimer Therapies Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Anti-β-Alzheimer Therapies Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Anti-β-Alzheimer Therapies Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 16-Mar-2021